Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBT Margin (2021 - 2025)

Aligos Therapeutics' EBT Margin history spans 5 years, with the latest figure at 11746.15% for Q4 2025.

  • For Q4 2025, EBT Margin fell 925758.0% year-over-year to 11746.15%; the TTM value through Dec 2025 reached 1092.36%, up 98345.0%, while the annual FY2025 figure was 1092.36%, 253212.0% up from the prior year.
  • EBT Margin reached 11746.15% in Q4 2025 per ALGS's latest filing, down from 4248.45% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 13868.49% in Q1 2025 to a low of 16368.57% in Q1 2023.
  • Average EBT Margin over 5 years is 2792.01%, with a median of 1776.41% recorded in 2021.
  • Peak YoY movement for EBT Margin: plummeted -1498537bps in 2023, then soared 1888852bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 10292.1% in 2021, then skyrocketed by 98bps to 157.02% in 2022, then crashed by -785bps to 1389.85% in 2023, then plummeted by -79bps to 2488.58% in 2024, then plummeted by -372bps to 11746.15% in 2025.
  • Per Business Quant, the three most recent readings for ALGS's EBT Margin are 11746.15% (Q4 2025), 4248.45% (Q3 2025), and 1624.66% (Q2 2025).